NeuroOne Medical Technologies Corporation — FY2019 Form 10-K
Reporting period: Fiscal year ended September 30, 2019. This is an annual report, not a standalone fourth-quarter report. The company develops thin-film electrodes for brain monitoring and potential ablation and stimulation; it had no commercial product revenue during the fiscal year.
Financial performance and position
- Revenue: $0 from product sales. Gross margin is not meaningful because the company had no commercial sales.
- Operating expenses: $5.81 million, up $1.65 million from the comparable 12-month 2018 period. General and administrative expense was $4.28 million (up $1.07 million); research and development was $1.53 million (up $0.58 million).
- Net loss: $6.78 million, approximately unchanged from $6.76 million in the comparable 12-month 2018 period. Loss from operations was $5.81 million. Basic and diluted loss per share was $0.57, versus $0.61 in the 2018 comparison.
- Cash flow: Net cash used in operations was $5.40 million, versus $2.84 million in the comparable 12-month 2018 MD&A comparison. Investing used $0.12 million; financing provided $5.77 million, principally from equity and warrant offerings.
- Liquidity at year-end: Cash was $0.26 million and current assets were $0.30 million. Current liabilities were $1.77 million, implying a working-capital deficit of approximately $1.47 million. The company reported no convertible notes or unsecured loans outstanding at September 30, 2019; accounts payable were $1.15 million and accrued expenses $0.62 million.
- Capital position: Accumulated deficit was $17.24 million; stockholders’ deficit was $1.24 million. The company had 13.49 million shares outstanding at September 30, 2019 and 7.27 million warrants outstanding.
Period-comparison caveat: The MD&A compares FY2019 with the 12 months ended September 30, 2018. The audited financial-statement comparative column instead presents the nine-month transition period ended September 30, 2018, following a change in fiscal year-end. Confirm the comparison basis when reviewing individual figures.
Material changes and developments
- Operating expenses rose substantially, driven by development activity, personnel, legal, accounting and public-company costs; lower interest expense and note-extinguishment losses largely offset that increase, leaving net loss broadly flat.
- Convertible notes were converted into common stock and warrants during 2018 and February 2019. The company ended FY2019 with no debt shown on its balance sheet, but its cash resources remained limited.
- After year-end, the company reported FDA 510(k) clearance for its Evo cortical electrode for temporary brain-surface recording, monitoring and stimulation. The clearance occurred in the fourth calendar quarter of 2019, after the September 30 fiscal year-end; commercial launch was described as in process.
- After year-end, the company raised $0.3 million gross in an October 2019 stock sale and issued $3.23 million principal amount of 13% convertible notes through December 3, 2019. Those notes mature May 1, 2020, with accrued interest, unless converted under specified financing terms; warrants were also issued.
Outlook, risks and unusual items
- Funding and going concern: Management said year-end cash would not fund operating needs. The auditor’s report includes a going-concern explanatory paragraph, citing recurring losses and negative operating cash flows that raise substantial doubt about the company’s ability to continue. Management planned further financing and expense controls; no assurance of funding is given.
- Development and commercialization: FDA clearance applied to the initial cortical diagnostic product, not the broader planned depth-electrode, minimally invasive delivery, ablation, chronic stimulation or spinal-cord products. Those programs remained in development and could require further testing, clinical evidence and regulatory approvals. No revenue forecast or quantified sales guidance is provided.
- License milestone: WARF could terminate its license on notice if the company did not have commercial sales of an FDA-approved licensed product by March 31, 2020. The license also carries minimum annual royalties of $50,000 for 2019, $100,000 for 2020 and $150,000 annually thereafter, plus sales-based royalties.
- Legal contingency: PMT litigation alleged restrictive-covenant, trade-secret and related claims against the company and individuals. One claim was dismissed, while other claims remained; a sanctions hearing was scheduled for December 2019 and any remaining claims were expected to go to trial in May 2020. The filing does not provide a clear quantified estimate of potential loss.
- Other key risks: Dependence on additional capital, potential shareholder dilution, limited operating history, reimbursement and adoption uncertainty, competition from larger device companies, reliance on WARF/Mayo and outsourced manufacturers, and product-liability exposure. The company said prior internal-control material weaknesses were remediated by September 30, 2019; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Current cash, operating burn and financing needs, including the status and repayment or conversion of the 13% notes due May 2020.
- Commercial launch progress, sales, pricing, reimbursement and adoption following the post-year-end FDA clearance.
- Whether WARF’s March 31, 2020 commercial-sales milestone was met and whether license terms remain in good standing.
- Latest status and potential financial exposure of PMT litigation and any other legal contingencies.
- Fully diluted share count, including outstanding warrants, options and subsequent financing instruments, and the potential dilution from future capital raises.
- The basis for period comparisons: FY2018 MD&A figures cover 12 months, while the audited comparative statements cover a nine-month transition period.